Life-Threatening Bleeding Due to an Acquired Inhibitor to Factor Xii-Xi Successfully Treated With‘activated’prothrombin Complex Concentrate (Feiba)

Rolović, Z; Elezović, Ivo; Obrenovic, B.; Rizza, CR

doi:10.1111/j.1365-2141.1982.tb02830.x

Cited by 16 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…62 The employed assay in this study, however, might also record the recently discovered plasminogen activator inhibitor. 34 It is of interest that immunoglobulins inhibitory for Factor XII-XI can be acquired and that bleeding problems have been observed in some cases 14,110,169 and recurrent thrombosis in another. 1 It appears worthwhile in such situations to explore the relative inhibition of the "anticoagulants" in coagulation and fibrinolysis.…”

Section: Man: Somatic Diseasesmentioning

confidence: 99%

Role of the Contact System in Fibrinolysis

Kluft¹,

Dooijewaard²,

Emeis³

1987

Semin Thromb Hemost

154

View full text Add to dashboard Cite

Section: Man: Somatic Diseasesmentioning

confidence: 99%

Role of the Contact System in Fibrinolysis

Kluft¹,

Dooijewaard²,

Emeis³

1987

Semin Thromb Hemost

154

View full text Add to dashboard Cite

“…Although some exceptions of life‐threatening bleeding have been recorded [13], haemorrhagic manifestations associated with FXI inhibitor are mild or inexistant; indeed, most patients remain haemostatically normal [4]. In our patient, an incidental finding of a prolonged APTT led to the diagnosis of severe FXI deficiency.…”

Section: Discussionmentioning

confidence: 72%

A case of chronic myelomonocytic leukaemia and factor XI deficiency with a circulating anticoagulant

Billon¹,

Blouch²,

Escoffre‐Barbe³

et al. 2001

Haemophilia

View full text Add to dashboard Cite

Inhibitors against factor XI (FXI) have been frequently described in patients who acquired inhibitors (due to auto‐inmune disorders, malignancies or infections), but less often in those with a congenital deficiency of this factor, who had received plasma infusions. The present report concerns one such inhibitor found in the plasma of a patient with chronic myelomonocytic leukaemia and infected by B19 parvovirus, who was neither a heterozygote nor a homozygote for FXI deficiency, and who had no bleeding tendency despite a very low FXI level. Taking this case into account, we discuss and present the clinical and biological features of acquired FXI deficiency caused by an inhibitor.

show abstract

“…While there are reports of spontaneously acquired FXI inhibitors, most reported patients did not bleed, therefore, they were either observed or given steroids [2]. Only two patients out of 12 with spontaneous FXI inhibitor were given FFP and FEIBA Ò for dilatation and curettage and total hysterectomy, respectively [3,4]. Morgan et al reported two patients with FXI de®ciency and inhibitors who were treated with large amounts of FFP for transurethral prostatectomy and gastrointestinal bleeding from a gastric ulcer, respectively [5].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Management of factor XI inhibitor for cardiac intervention: successful treatment with immunosuppressive therapy and plasma exchange

Teruya

Styler

2000

Haemophilia

View full text Add to dashboard Cite

Two cases with congenital homozygous factor XI deficiency developed a factor XI inhibitor following repeated plasma transfusions. Case 1 was given cyclophosphamide, intravenous immunoglobulin, and steroids. The factor XI inhibitor disappeared on day 103 and cardiac catheterization was performed without complications after giving fresh frozen plasma. Case 2 was effectively managed by plasma exchange for cardiac catheterization and surgery. However, after five plasma exchange procedures, the same plasma volume exchange was not effective in shortening the activated partial thromboplastin time (APTT). A significant heparin rebound occurred 4 h after heparin neutralization with protamine sulphate for which the patient needed to have a blood clot evacuated from around the heart.

show abstract

Life-Threatening Bleeding Due to an Acquired Inhibitor to Factor Xii-Xi Successfully Treated With‘activated’prothrombin Complex Concentrate (Feiba)

Cited by 16 publications

References 2 publications

Role of the Contact System in Fibrinolysis

Role of the Contact System in Fibrinolysis

A case of chronic myelomonocytic leukaemia and factor XI deficiency with a circulating anticoagulant

Management of factor XI inhibitor for cardiac intervention: successful treatment with immunosuppressive therapy and plasma exchange

Contact Info

Product

Resources

About